drugset / Trial / NCT00141726

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

NCT00141726

Phase 2 Completed 34 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness of etanercept in the treatment of patients with sub-acute lung injury following a bone marrow transplant. This study will also examine the toxicity of treatment with etanercept as well as whether there is an improved quality of life in these patients.

Timeline

Start
2003-10
Primary completion
2008-07
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 0.4 mg/kg Subcutaneous